The demand for high-quality and well-annotated biospecimens has been rising due to a growing focus on personalized medicine. Researchers and their biospecimen sourcing channels need to consider inclusion/exclusion criteria, pre-analytical considerations, and respect of laws, ethics, and other regulations around sourcing human biospecimens (HBS).
This workshop will discuss these considerations, the essential upfront planning needed in sourcing HBS, and how they can affect R&D projects followed by a live Q&A panel with our sourcing experts.
- The importance of choosing the right biospecimen provider to obtain fit-for-purpose samples
- Advantages and limitations of the different types of collections
- Limitations of sample availability in different countries as well as the impact of different Standards of Care (SOC)
- Importance of traceability
- Other considerations
Eva Jordan, Ph.D.
Eva has a Ph.D. in Biochemistry from the University of Leicester, and was previously Biobank Manager at the Nottingham Biobank. Eva joined the Azenta Biospecimen Sourcing Team in 2018, where she leads a team specialized in procurement of human biological samples.
Maya George, Ph.D.
Maya has a Ph.D. in Pharmaceutics from the University of Iowa and previously managed World Health Organization (WHO)-endorsed global pandemic preparedness research programs. In 2019, Maya joined the Azenta Biospecimen Sourcing Team where she leads a team specialized in complex procurement of human biological samples.
Vanessa Tumilasci, Ph.D.
Vanessa has a Ph.D. in Immunology from McGill University and over 10 years of experience in the life science services industry. She joined Azenta Life Sciences in 2016 as a Project Manager, and today she is the Director of Biospecimen Sourcing Services leading the unit commercial activities.
Complete the form to watch the workshop on-demand!